Printer friendly

What does H43M stand for?

H43M stands for His-43-->Met mutation

This definition appears rarely

Samples in periodicals archive:

These new MET mutations, when introduced into mouse MET cDNA and transfected into NIH3T3 cells, stimulated focus formation. Mutants Y1248D, V1110I, H1112Y, H1112L and H1124D produced an average of 2, 12, 30, 36 and 36 foci per g DNA, respectively, from three separate experiments (data not shown). No foci were produced in transfections with the wild type MET construct or empty vector. It should be noted that when MET T1010I, thought to be a rare polymorphism, was introduced into NIH3T3 cells, neither focus formation nor constitutive MET phosphorylation was observed (data not shown).
15 ). In physiological conditions this program elicits the formation of epithelial and endothelial tubular structures (the so called “branched morphogenesis”), myoblast migration, and neurite branching. The deregulated activation of the invasive growth might confer metastatic and invasive properties to transformed cells. In cell culture, it was demonstrated that mutated MET receptors identified in papillary renal cell carcinoma transform transfected cells and enable them to invade extracellular matrix through the interaction with specific signal transducers (16). In the mouse model, metastases were obtained in animals transplanted with cells coexpressing the ligand SF1/HGF and the MET receptor, and in transgenic animals expressing the MET kinase activated by mutation.
In 2004, investigators discovered a class of activating mutations in the tyrosine kinase domain of the EGFR that are associated with sensitivity to EGFR-TKI therapy. 7,8,13 In-frame deletions in exon 19 or substitution of arginine for leucine at position 858 (L858R) in exon 21 account for about 85% of mutations in this receptor. 18 With the creation and analysis of a database encompassing multiple prospective trials of gefitinib or erlotinib in the first-line setting, improved response rates, median time to progression, and median survival were demonstrated for patients harboring one of these mutations compared to those who are wild-type for EGFR.
MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions.
The importance of haem-iron axial coordination in flavocytochrome b2 (L-lactate: cytochrome-c oxidoreductase) has been examined by replacing one of the ligating histidines, His-43, with methionine. The His-43-->Met mutation (H43M) results in a distinct colour change from red in the wild-type enzyme to green in the mutant enzyme. The electronic absorption spectrum indicates that only approx.
Research participants were consented to participate in a study of genetic factors leading to colon cancer risk. Ascertainment and collection of the sibling pair study cohort have been previously described [5]. Briefly, 169 siblings (148 affected with CRC and 21 unaffected) from families with two siblings diagnosed with colorectal adenocarcinoma or a polyp with high grade dysplasia and all of age > 20 years were included. A young onset population, defined as a CRC diagnosis = 50 years (n = 130) and a familial colon cancer cohort, defined as two first-degree relatives diagnosed with CRC (n = 169), was used for confirmation of the MET p. T992I mutation.